Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 438 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: coagulation study Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Hemorrhagic Radiation Proctitis Using the Halo System

NCT01103492
View directory record Official record
Conditions
Pelvic Neoplasms
Interventions
HALO90 Ablation catheter
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

NCT01477528
View directory record Official record
Conditions
Anticoagulation, Left Ventricular Assist Device
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
San Diego, California • Gainesville, Florida • Oak Lawn, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Individualizing Hemophilia Prophylaxis Using Thromboelastography

NCT02582060
View directory record Official record
Conditions
Hemophilia A
Interventions
Thromboelastography/Thromboelastometry-Guided Treatment Regimen
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 70 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A New Paradigm for Vitamin D Sufficiency

NCT02969850
View directory record Official record
Conditions
New Biomarkers for Measuring Vitamin D Level
Interventions
Vitamin D Supplementation, Placebo, Calcium
Dietary Supplement · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational Results available

A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients

NCT02086682
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Dialysis, Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
Marie Hogan
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nattokinase Atherothrombotic Prevention Study

NCT02080520
View directory record Official record
Conditions
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Interventions
Nattokinase, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 100 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D and Calcium Study

NCT00857831
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Vitamin D and Calcium
Dietary Supplement
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

NCT00329797
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
Dietary Supplement · Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
80
States / cities
Chico, California • Los Angeles, California • Pomona, California + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Plasma Adsorption in Patients With Confirmed COVID-19

NCT04358003
View directory record Official record
Conditions
Respiratory Failure, ARDS
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Device
Lead sponsor
Marker Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty

NCT03952546
View directory record Official record
Conditions
Surgical Blood Loss
Interventions
Saline-coupled Bipolar Sealer, Unipolar electrocautery
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Syosset, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

NCT00283088
View directory record Official record
Conditions
Stroke
Interventions
hypothermia, tissue plasminogen activator
Procedure · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Hartford, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

NCT02298842
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Platelets stored in InterSol, Platelets stored in Plasma
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 2:24 AM EDT
Not listed Not applicable Interventional

Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement

NCT03557242
View directory record Official record
Conditions
Aortic Stenosis
Interventions
TAVR, Warfarin plus Aspirin, Aspirin Only
Device · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
San Diego, California • Washington D.C., District of Columbia • Ridgewood, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea

NCT00936481
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

NCT04548791
View directory record Official record
Conditions
Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor
Interventions
Coagulation Factor VIIa variant
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 23, 2026, 2:24 AM EDT
Withdrawn Phase 3 Interventional

Emicizumab PUPs and Nuwiq ITI Study

NCT04030052
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 3 Interventional

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173
View directory record Official record
Conditions
Congenital Antithrombin Deficiency
Interventions
Atenativ
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Miami, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

NCT00243659
View directory record Official record
Conditions
Hemophilia A
Interventions
ReFacto AF
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
12 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
La Jolla, California • Detroit, Michigan • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

NCT00157105
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional Results available

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

NCT00243386
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
7 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 23, 2026, 2:24 AM EDT